MA47206A - Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 - Google Patents
Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3Info
- Publication number
- MA47206A MA47206A MA047206A MA47206A MA47206A MA 47206 A MA47206 A MA 47206A MA 047206 A MA047206 A MA 047206A MA 47206 A MA47206 A MA 47206A MA 47206 A MA47206 A MA 47206A
- Authority
- MA
- Morocco
- Prior art keywords
- tim
- antibodies
- cancer treatment
- treatment methods
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444354P | 2017-01-09 | 2017-01-09 | |
| US201762582272P | 2017-11-06 | 2017-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47206A true MA47206A (fr) | 2019-11-13 |
Family
ID=61163782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047206A MA47206A (fr) | 2017-01-09 | 2018-01-09 | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11926665B2 (OSRAM) |
| EP (1) | EP3565594A1 (OSRAM) |
| JP (2) | JP7118073B2 (OSRAM) |
| KR (1) | KR102671283B1 (OSRAM) |
| CN (1) | CN110382000A (OSRAM) |
| AU (1) | AU2018205401B2 (OSRAM) |
| BR (1) | BR112019014169A2 (OSRAM) |
| CA (1) | CA3049536A1 (OSRAM) |
| IL (1) | IL267803A (OSRAM) |
| MA (1) | MA47206A (OSRAM) |
| MX (1) | MX2019008208A (OSRAM) |
| SG (1) | SG10201913083SA (OSRAM) |
| TW (2) | TWI841209B (OSRAM) |
| WO (1) | WO2018129553A1 (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6815329B2 (ja) | 2015-03-23 | 2021-01-20 | バイエル ファーマ アクチエンゲゼルシャフト | 抗ｃｅａｃａｍ６抗体およびその使用 |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EP3534950A4 (en) * | 2016-11-01 | 2020-05-06 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| BR112019008861A2 (pt) * | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| MX2019008207A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-pd-1. |
| CA3049536A1 (en) * | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| KR20200018436A (ko) | 2017-05-09 | 2020-02-19 | 테사로, 인코포레이티드 | 암 치료를 위한 조합 요법 |
| CA3063715A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
| EA202090573A1 (ru) | 2017-09-26 | 2020-09-07 | Тесаро, Инк. | Составы нирапариба |
| JP2020536066A (ja) | 2017-09-30 | 2020-12-10 | テサロ， インコーポレイテッド | 癌を治療するための併用療法 |
| CN111182923A (zh) | 2017-10-06 | 2020-05-19 | 特沙诺有限公司 | 组合疗法及其用途 |
| WO2019143607A1 (en) * | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| EP3860988A1 (en) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| ES2967517T3 (es) | 2018-10-03 | 2024-04-30 | Tesaro Inc | Sales de niraparib |
| CA3117429A1 (en) * | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Anti-tim-3 antibodies |
| KR20210104704A (ko) | 2018-12-19 | 2021-08-25 | 바이엘 악티엔게젤샤프트 | 항 ceacam6 및 tim3 항체의 제약 조합물 |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| US20220089740A1 (en) * | 2019-01-11 | 2022-03-24 | Eli Lilly And Company | Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| CN115698075A (zh) | 2020-04-14 | 2023-02-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗 |
| WO2021209356A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| JP2024515263A (ja) | 2021-04-09 | 2024-04-08 | オーエスイー・イミュノセラピューティクス | 改善された特性を有する二機能性分子のための新規足場構造 |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| BR112023020918A2 (pt) * | 2021-04-13 | 2023-12-12 | Medimmune Llc | Anticorpo biespecífico direcionado a pd-1 e tim-3 |
| EP4326773A4 (en) | 2021-04-23 | 2025-09-24 | Suzhou Neologics Bioscience Co Ltd | ANTIBODIES TARGETING TIM-3 AND THEIR USES |
| US11970548B2 (en) * | 2021-08-27 | 2024-04-30 | Innovative Cellular Therapeutics Holdings, Ltd. | Nanobody target GCC and uses in chimeric antigen receptor cell therapy |
| IL310773A (en) | 2021-09-02 | 2024-04-01 | Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts | Anti-CECAM6 antibodies with reduced side effects |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| CN119907811A (zh) | 2022-08-02 | 2025-04-29 | Ose免疫疗法公司 | 针对cd28的多功能分子 |
| TW202440634A (zh) * | 2023-03-08 | 2024-10-16 | 美商英塞特公司 | 用於治療癌症之抗－ｐｄ－１活性劑、抗－ｔｉｍ－３活性劑及抗－ｌａｇ－３活性劑之組合療法 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2025014933A1 (en) * | 2023-07-10 | 2025-01-16 | Northwestern University | Targeting tim-3 in mapk-driven glioma |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| AU2001233212A1 (en) | 2000-02-02 | 2001-08-14 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| EP4091631A1 (en) | 2002-01-30 | 2022-11-23 | The Brigham and Women's Hospital, Inc. | A tim-3 binding molecule for use in the treatment of a disease |
| AU2003262386A1 (en) | 2002-04-17 | 2003-11-03 | Michael R. Blaese | Short fragment homologous replacement to provide bse resistant cattle |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| US7824681B2 (en) | 2005-08-16 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies that specifically bind IGF-II |
| SG173385A1 (en) | 2006-07-14 | 2011-08-29 | Ac Immune S A Ch | Humanized antibody against amyloid beta |
| KR20180043854A (ko) | 2006-07-14 | 2018-04-30 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
| CA2662549C (en) | 2006-09-08 | 2014-10-28 | Amgen Inc. | Il-1 family variants |
| PL2805945T3 (pl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp) |
| CA2678451A1 (en) | 2007-02-20 | 2008-08-28 | Robert A. Horlick | Somatic hypermutation systems |
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| ES2548131T3 (es) | 2008-01-08 | 2015-10-14 | Merck Sharp & Dohme Limited | Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
| AU2009285585A1 (en) | 2008-08-28 | 2010-03-04 | Wyeth Llc | Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases |
| JP6158511B2 (ja) | 2010-06-11 | 2017-07-05 | 協和発酵キリン株式会社 | 抗ｔｉｍ−３抗体 |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| HK1199883A1 (en) | 2011-08-26 | 2015-07-24 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| EP3536710B1 (en) | 2011-11-16 | 2025-10-29 | Boehringer Ingelheim International GmbH | Anti il-36r antibodies |
| SI2797952T1 (sl) | 2011-12-28 | 2019-07-31 | Immunoqure Ag | Postopek za pripravo monoklonskih avto-protiteles z želeno specifičnostjo |
| NZ702269A (en) | 2012-06-15 | 2017-07-28 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| JP6162319B2 (ja) | 2013-03-12 | 2017-07-12 | デシミューン セラピューティクス，インコーポレイテッド | ヒト化抗ｎ２抗体 |
| ES2926773T3 (es) | 2013-03-15 | 2022-10-28 | Novo Nordisk As | Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular |
| ES2845609T3 (es) | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| SI3215532T1 (sl) | 2014-11-06 | 2020-02-28 | F. Hoffmann-La Roche Ag | Protitelesa proti TIM3 in postopki uporabe |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| EP3504243B1 (en) | 2016-08-26 | 2024-07-24 | BeiGene Switzerland GmbH | Anti-tim-3 antibodies and use thereof |
| BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| CA3049536A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| AR111651A1 (es) * | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
-
2018
- 2018-01-09 CA CA3049536A patent/CA3049536A1/en active Pending
- 2018-01-09 MX MX2019008208A patent/MX2019008208A/es unknown
- 2018-01-09 WO PCT/US2018/013021 patent/WO2018129553A1/en not_active Ceased
- 2018-01-09 TW TW112102836A patent/TWI841209B/zh active
- 2018-01-09 JP JP2019537099A patent/JP7118073B2/ja active Active
- 2018-01-09 KR KR1020197023158A patent/KR102671283B1/ko active Active
- 2018-01-09 CN CN201880016126.4A patent/CN110382000A/zh active Pending
- 2018-01-09 EP EP18703388.1A patent/EP3565594A1/en active Pending
- 2018-01-09 US US16/476,534 patent/US11926665B2/en active Active
- 2018-01-09 AU AU2018205401A patent/AU2018205401B2/en active Active
- 2018-01-09 BR BR112019014169-3A patent/BR112019014169A2/pt unknown
- 2018-01-09 SG SG10201913083SA patent/SG10201913083SA/en unknown
- 2018-01-09 TW TW107100821A patent/TWI793094B/zh active
- 2018-01-09 MA MA047206A patent/MA47206A/fr unknown
-
2019
- 2019-07-02 IL IL267803A patent/IL267803A/en unknown
-
2022
- 2022-04-05 JP JP2022062862A patent/JP7472190B2/ja active Active
-
2024
- 2024-02-02 US US18/430,835 patent/US20240301057A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202319068A (zh) | 2023-05-16 |
| JP2020503364A (ja) | 2020-01-30 |
| IL267803A (en) | 2019-09-26 |
| KR20190098263A (ko) | 2019-08-21 |
| MX2019008208A (es) | 2019-12-11 |
| TWI793094B (zh) | 2023-02-21 |
| JP7472190B2 (ja) | 2024-04-22 |
| BR112019014169A2 (pt) | 2020-02-11 |
| TWI841209B (zh) | 2024-05-01 |
| KR102671283B1 (ko) | 2024-06-03 |
| AU2018205401A1 (en) | 2019-07-25 |
| CN110382000A (zh) | 2019-10-25 |
| JP7118073B2 (ja) | 2022-08-15 |
| JP2022087185A (ja) | 2022-06-09 |
| EP3565594A1 (en) | 2019-11-13 |
| TW201831196A (zh) | 2018-09-01 |
| SG10201913083SA (en) | 2020-03-30 |
| CA3049536A1 (en) | 2018-07-12 |
| US11926665B2 (en) | 2024-03-12 |
| US20190322746A1 (en) | 2019-10-24 |
| AU2018205401B2 (en) | 2025-01-02 |
| US20240301057A1 (en) | 2024-09-12 |
| WO2018129553A1 (en) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47206A (fr) | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 | |
| MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
| MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
| EP3723803A4 (en) | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES | |
| EP3752180A4 (en) | METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES | |
| EP3581651A4 (en) | ANTI-GPRC5D ANTIBODY AND MOLECULE WITH IT | |
| EP3454945A4 (en) | ASH11 INHIBITORS AND METHOD FOR TREATING THEM | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| EP3687981A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | |
| MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
| MA52657A (fr) | Anticorps spécifiques d'axl pour le traitement du cancer | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| EP3606544A4 (en) | MINIGENT THERAPY | |
| EP3606531A4 (en) | METHOD OF TREATMENT OF CANCER | |
| EP3773632A4 (en) | Methods of treating egfrviii expressing glioblastomas | |
| CO2017001087A2 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
| EP3344767A4 (en) | SMALL MOLECULAR MEDIATED SIZE SELECTION OF NUCLEIC ACIDS | |
| EP3373937A4 (en) | ANTI-CD22 ANTIBODY MAYTANSIN CONJUGATES AND METHOD OF USE THEREOF | |
| EP3688023A4 (en) | PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT | |
| EP3681498A4 (en) | PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT | |
| EP3638293A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER | |
| EP3787625A4 (en) | METHODS OF TREATMENT OF CANCER |